Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13241481 | 0.98 | MEN1 (0.56) | MEN1KMT2AMAOBALOX5CYP1A2 | |
| SCHEMBL5027658 | 0.98 | MEN1 (0.56) | MEN1KMT2AMAOBALOX5CYP1A2 | |
| SCHEMBL21429714 | 0.96 | MAOB (0.55) | MEN1KMT2AMAOBALOX5CYP1A2 | |
| SCHEMBL21582181 | 0.91 | MAOB (0.65) | MEN1KMT2AMAOBBCHETSHR | |
| SCHEMBL9999624 | 0.90 | MAOB (0.50) | MEN1KMT2AMAOBALOX5CYP1A2 | |
| SCHEMBL9454219 | 0.88 | GRM5 (0.54) | MEN1KMT2AMAOBALOX5CYP1A2 | |
| SCHEMBL4674930 | 0.87 | MEN1 (0.70) | MEN1KMT2AMAOBALOX5CYP1A2 | |
| SCHEMBL80829 | 0.86 | MAOB (0.68) | MAOBALOX5BCHECYP4F2CYP4A11 | |
| SCHEMBL29411728 | 0.86 | MAOB (0.68) | MAOBALOX5BCHECYP4F2CYP4A11 | |
| SCHEMBL2809203 | 0.86 | MAOB (0.50) | MEN1KMT2AMAOBALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001060774-A1 | SYNTHESIS OF RESVERATROL | BRIGHAM YOUNG UNIVERSITY (US) | 2001-08-23 | — | — | WO | claimed |
| CN-114890896-B | Dendritic (methyl) acrylic ester monomer and preparation method and application thereof | 中国科学院理化技术研究所 | 2023-07-07 | — | — | CN | disclosed |
| CN-114890896-A | Dendritic (methyl) acrylate monomer and preparation method and application thereof | 中国科学院理化技术研究所 | 2022-08-12 | — | — | CN | disclosed |
| EP-3094318-B1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | KANNALIFE SCIENCES INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3094318-B1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | KANNALIFE SCIENCES INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20050270614-A1 | Photochromic device | YAMANASHI TLO CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| US-20040210058-A1 | Photochromic compound, photochromic composition and photochromic display element using the same | YAMANASHI TLO CO., LTD. (JP) | 2004-10-21 | — | — | US | disclosed |
| EP-1469056-A2 | Photochromic compound, photochromic composition and photochromic display element using the same | Yamanashi TLO Co. Ltd. (JP) | 2004-10-20 | — | — | EP | disclosed |
| WO-2001060774-A1 | SYNTHESIS OF RESVERATROL | BRIGHAM YOUNG UNIVERSITY (US) | 2001-08-23 | — | — | WO | disclosed |
| US-5807837-A | ADMINISTERING TO TREAT HIV INFECTIONS TO INHIBIT THE REPLICATION OF FOREIGN NUCLEIC ACIDS IN A NORMAL CELL | SANKYO COMPANY, LIMITED (JP) | 1998-09-15 | — | — | US | disclosed |
| US-5674856-A | TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS | SANKYO COMPANY, LIMITED (JP) | 1997-10-07 | — | — | US | disclosed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0558749-A1 | ANTISENSE NUCLEIC ACID DERIVATIVE | SANKYO COMPANY LIMITED (JP) | 1993-09-08 | — | — | EP | disclosed |
| US-5041516-A | Macromolecules | CORNELL RESEARCH FOUNDATION, INC. (US) | 1991-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | TXNRD2, KEAP1, GOT2 | MEN1 3497/4885KMT2A 3403/4885MAOB 224/4885 |
| US-20040210058-A1 | Photochromic compound, photochromic composition and photochromic display element using the same | EPB41L2, TYR, SBDS | MEN1 4405/4885KMT2A 1723/4885MAOB 1519/4885 |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | TXNRD2, KEAP1, GOT2 | MEN1 3497/4885KMT2A 3403/4885MAOB 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.